Literature DB >> 14528023

A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen.

Sigrid A Rajasekaran1, Gopalakrishnapillai Anilkumar, Eri Oshima, James U Bowie, He Liu, Warren Heston, Neil H Bander, Ayyappan K Rajasekaran.   

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed at high levels in prostate cancer and in tumor-associated neovasculature. In this study, we report that PSMA is internalized via a clathrin-dependent endocytic mechanism and that internalization of PSMA is mediated by the five N-terminal amino acids (MWNLL) present in its cytoplasmic tail. Deletion of the cytoplasmic tail abolished PSMA internalization. Mutagenesis of N-terminal amino acid residues at position 2, 3, or 4 to alanine did not affect internalization of PSMA, whereas mutation of amino acid residues 1 or 5 to alanine strongly inhibited internalization. Using a chimeric protein composed of Tac antigen, the alpha-chain of interleukin 2-receptor, fused to the first five amino acids of PSMA (Tac-MWNLL), we found that this sequence is sufficient for PSMA internalization. In addition, inclusion of additional alanines into the MWNLL sequence either in the Tac chimera or the full-length PSMA strongly inhibited internalization. From these results, we suggest that a novel MXXXL motif in the cytoplasmic tail mediates PSMA internalization. We also show that dominant negative micro2 of the adaptor protein (AP)-2 complex strongly inhibits the internalization of PSMA, indicating that AP-2 is involved in the internalization of PSMA mediated by the MXXXL motif.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528023      PMCID: PMC284788          DOI: 10.1091/mbc.e02-11-0731

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  56 in total

1.  The leucine-based sorting motifs in the cytoplasmic domain of the invariant chain are recognized by the clathrin adaptors AP1 and AP2 and their medium chains.

Authors:  M W Hofmann; S Höning; D Rodionov; B Dobberstein; K von Figura; O Bakke
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Targeting of membrane proteins to endosomes and lysosomes.

Authors:  I V Sandoval; O Bakke
Journal:  Trends Cell Biol       Date:  1994-08       Impact factor: 20.808

3.  Systematic mutational analysis of the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor cytoplasmic domain. An acidic cluster containing a key aspartate is important for function in lysosomal enzyme sorting.

Authors:  H J Chen; J Yuan; P Lobel
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

4.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

5.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury.

Authors:  B S Slusher; J J Vornov; A G Thomas; P D Hurn; I Harukuni; A Bhardwaj; R J Traystman; M B Robinson; P Britton; X C Lu; F C Tortella; K M Wozniak; M Yudkoff; B M Potter; P F Jackson
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 6.  Signal-dependent membrane protein trafficking in the endocytic pathway.

Authors:  I S Trowbridge; J F Collawn; C R Hopkins
Journal:  Annu Rev Cell Biol       Date:  1993

7.  Release of endogenous N-acetylaspartylglutamate (NAAG) and uptake of [3H]NAAG in guinea pig cerebellar slices.

Authors:  M Sekiguchi; K Okamoto; Y Sakai
Journal:  Brain Res       Date:  1989-03-13       Impact factor: 3.252

8.  A single amino acid change in the cytoplasmic domain allows the influenza virus hemagglutinin to be endocytosed through coated pits.

Authors:  J Lazarovits; M Roth
Journal:  Cell       Date:  1988-06-03       Impact factor: 41.582

9.  Constitutive and antibody-induced internalization of prostate-specific membrane antigen.

Authors:  H Liu; A K Rajasekaran; P Moy; Y Xia; S Kim; V Navarro; R Rahmati; N H Bander
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701

10.  Interaction of tyrosine-based sorting signals with clathrin-associated proteins.

Authors:  H Ohno; J Stewart; M C Fournier; H Bosshart; I Rhee; S Miyatake; T Saito; A Gallusser; T Kirchhausen; J S Bonifacino
Journal:  Science       Date:  1995-09-29       Impact factor: 47.728

View more
  75 in total

1.  Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells.

Authors:  Xiao-Yan Zhao; Hsiao-Lai Liu; Bing Liu; Joerg Willuda; Gerhard Siemeister; Mithra Mahmoudi; Harald Dinter
Journal:  Transl Oncol       Date:  2008-07       Impact factor: 4.243

Review 2.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

3.  Development of targeted near-infrared imaging agents for prostate cancer.

Authors:  Xinning Wang; Steve S Huang; Warren D W Heston; Hong Guo; Bing-Cheng Wang; James P Basilion
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

4.  Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.

Authors:  Mariz Kasoha; Clara Unger; Erich-Franz Solomayer; Rainer M Bohle; Claudia Zaharia; Fadi Khreich; Stefan Wagenpfeil; Ingolf Juhasz-Böss
Journal:  Clin Exp Metastasis       Date:  2018-02-10       Impact factor: 5.150

Review 5.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  A Fluorescent, [18F]-Positron-Emitting Agent for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells.

Authors:  Hua Guo; Harikrishna Kommidi; Yogindra Vedvyas; Jaclyn E McCloskey; Weiqi Zhang; Nandi Chen; Fuad Nurili; Amy P Wu; Haluk B Sayman; Oguz Akin; Erik A Rodriguez; Omer Aras; Moonsoo M Jin; Richard Ting
Journal:  ACS Chem Biol       Date:  2019-06-17       Impact factor: 5.100

Review 7.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

8.  Membrane Protein Dimerization in Cell-Derived Lipid Membranes Measured by FRET with MC Simulations.

Authors:  Jan Škerle; Jana Humpolíčková; Nicholas Johnson; Petra Rampírová; Edita Poláchová; Monika Fliegl; Jan Dohnálek; Anna Suchánková; David Jakubec; Kvido Strisovsky
Journal:  Biophys J       Date:  2020-03-29       Impact factor: 4.033

9.  In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen.

Authors:  Tiancheng Liu; Lisa Y Wu; Joseph K Choi; Clifford E Berkman
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

10.  Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA).

Authors:  Sachin S Chandran; Sangeeta R Banerjee; Ron C Mease; Martin G Pomper; Samuel R Denmeade
Journal:  Cancer Biol Ther       Date:  2008-03-26       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.